Influx Healthtech Ltd vs Sai Parenterals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Influx Healthtech Ltd is ₹ 276.25 as of 05 May 15:30 . The P/E Ratio of Influx Healthtech Ltd is 0 as of March 2023 .The P/E Ratio of Sai Parenterals Ltd is 0 as of March 2023 . The Market Cap of Influx Healthtech Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Sai Parenterals Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Influx Healthtech Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Sai Parenterals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Influx Healthtech Ltd

Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre.
Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc.

About Sai Parenterals Ltd

Sai Parenteral's Limited was originally incorporated as Sai Parenteral's Private Limited', a Private Limited Company on January 12, 2001, with the Registrar of Companies, at Hyderabad.
Thereafter, Company was converted into a Public Limited Company and the name of Company was changed to Sai Parenteral's Limited' w.e.f January 17, 2022. Sai Parenteral's is a diversified pharmaceutical formulations company engaged in the business of Branded Generic Formulations and Contract Development and Manufacturing Organization (CDMO) products and services for the domestic and international markets.
Company has developed a comprehensive and diversified portfolio of complex pharmaceutical products, covering both high-value and high-volume categories addressing critical therapeutic needs across the multiple disease areas.

FAQs for the comparison of Influx Healthtech Ltd and Sai Parenterals Ltd

Which company has a larger market capitalization, Influx Healthtech Ltd or Sai Parenterals Ltd?

Market cap of Influx Healthtech Ltd is 649 Cr while Market cap of Sai Parenterals Ltd is 2,118 Cr

What are the key factors driving the stock performance of Influx Healthtech Ltd and Sai Parenterals Ltd?

The stock performance of Influx Healthtech Ltd and Sai Parenterals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Influx Healthtech Ltd and Sai Parenterals Ltd?

As of May 5, 2026, the Influx Healthtech Ltd stock price is INR ₹280.4. On the other hand, Sai Parenterals Ltd stock price is INR ₹479.5.

How do dividend payouts of Influx Healthtech Ltd and Sai Parenterals Ltd compare?

To compare the dividend payouts of Influx Healthtech Ltd and Sai Parenterals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.